Effects of growth hormone therapy on thyroid function of growth hormone-deficient adults with and without concomitant thyroxine-substituted central hypothyroidism.

Jørgensen JO, Pedersen SA, Laurberg P, Weeke J, Skakkebaek NE, Christiansen JS

The Journal of clinical endocrinology and metabolism1 Dec 1989Cited by 111 (Europe PMC)

PMID2685007DOI10.1210/jcem-69-6-1127PepBankPUB-02685007

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, GH produced similar decreases in serum free T4.
In plain wordsIn GH-deficient adults, GH reduced serum free T4 compared with placebo.
Peptide
HGH (somatotropin)
Outcome
DecreaseSerum free T4
Study
n = 22
Comparator
Placebo
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
2 IU/m2.day · 4 monthsAs given in this study (human).
Source sentences
Summary
Similar changes were seen in serum free T4 and T3.
3 context sentences(design, population, supporting numbers)
Summary · context
Serum T4 (nanomoles per L) decreased in both groups after GH treatment [group I, 100 +/- 8 (mean +/- SE) vs. 89 +/- 8 (P less than 0.01); group II, 145 +/- 18 vs. 115 +/- 10 (P less than 0.05)].
Summary · context
Therefore, we conducted a double blind, placebo-controlled cross-over study of the effect of 4 months of biosynthetic human GH therapy (Norditropin; 2 IU/m2.day) on thyroid function in GH-deficient adults (8 females and 14 males; mean +/- SE age, 23.8 +/- 1.2 yr).
Summary · context
One group (I) was euthyroid without T4 substitution (n = 13), whereas the other (group II) received T4 (n = 9).
Report a problemFND-0268500705
02HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, GH produced similar increases in serum free T3.
In plain wordsIn GH-deficient adults, GH increased serum free T3 compared with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum free T3
Study
n = 22
Comparator
Placebo
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
2 IU/m2.day · 4 monthsAs given in this study (human).
Source sentences
Summary
Similar changes were seen in serum free T4 and T3.
3 context sentences(design, population, supporting numbers)
Summary · context
Conversely, GH treatment caused an increase in serum T3 (nanomoles per L) in both groups [group I, 1.9 +/- 0.1 vs. 2.0 +/- 0.1 (P less than 0.1); group II, 1.7 +/- 0.1 vs. 1.9 +/- 0.1 (P less than 0.05)].
Summary · context
Therefore, we conducted a double blind, placebo-controlled cross-over study of the effect of 4 months of biosynthetic human GH therapy (Norditropin; 2 IU/m2.day) on thyroid function in GH-deficient adults (8 females and 14 males; mean +/- SE age, 23.8 +/- 1.2 yr).
Summary · context
One group (I) was euthyroid without T4 substitution (n = 13), whereas the other (group II) received T4 (n = 9).
Report a problemFND-0268500706
03HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, serum TSH decreased nonsignificantly in both groups during GH therapy.
In plain wordsIn GH-deficient adults, GH did not significantly reduce serum TSH compared with placebo.
Peptide
HGH (somatotropin)
Outcome
No significant changeSerum TSH
Study
n = 22
Comparator
Placebo
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
2 IU/m2.day · 4 monthsAs given in this study (human).
Source sentences
Summary
Serum TSH decreased in both groups during GH therapy, though not significantly.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we conducted a double blind, placebo-controlled cross-over study of the effect of 4 months of biosynthetic human GH therapy (Norditropin; 2 IU/m2.day) on thyroid function in GH-deficient adults (8 females and 14 males; mean +/- SE age, 23.8 +/- 1.2 yr).
Summary · context
One group (I) was euthyroid without T4 substitution (n = 13), whereas the other (group II) received T4 (n = 9).
Report a problemFND-0268500709
04HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, serum thyroglobulin remained unaltered during GH therapy and did not differ from that in the age-matched reference group.
In plain wordsIn GH-deficient adults, serum thyroglobulin did not change during GH treatment and matched that of the reference group.
Peptide
HGH (somatotropin)
Outcome
No significant changeSerum thyroglobulin
Study
n = 22
Comparator
Age-matched reference group
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
2 IU/m2.day · 4 monthsAs given in this study (human).
Source sentences
Summary
Serum thyroglobulin was unaltered and did not differ from that in the reference group.
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we conducted a double blind, placebo-controlled cross-over study of the effect of 4 months of biosynthetic human GH therapy (Norditropin; 2 IU/m2.day) on thyroid function in GH-deficient adults (8 females and 14 males; mean +/- SE age, 23.8 +/- 1.2 yr).
Summary · context
One group (I) was euthyroid without T4 substitution (n = 13), whereas the other (group II) received T4 (n = 9).
Report a problemFND-0268500710
05HumanNon-randomized trialEfficacy outcome
In GH-deficient adults without T4 substitution, GH reduced serum T4 from 100 to 89 nanomoles per L (P less than 0.01).
In plain wordsIn GH-deficient adults without thyroid replacement, GH reduced serum T4 compared with placebo.
Peptide
HGH (somatotropin)
Outcome
DecreaseSerum T4 without T4 substitution
Study
n = 13
Comparator
Placebo
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
2 IU/m2.day · 4 monthsAs given in this study (human).
Measurements
T4
100 nanomoles per L
group I, first value listed
T4
89 nanomoles per L
group I, after GH
Source sentences
Summary
Serum T4 (nanomoles per L) decreased in both groups after GH treatment [group I, 100 +/- 8 (mean +/- SE) vs. 89 +/- 8 (P less than 0.01); group II, 145 +/- 18 vs. 115 +/- 10 (P less than 0.05)].
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we conducted a double blind, placebo-controlled cross-over study of the effect of 4 months of biosynthetic human GH therapy (Norditropin; 2 IU/m2.day) on thyroid function in GH-deficient adults (8 females and 14 males; mean +/- SE age, 23.8 +/- 1.2 yr).
Summary · context
One group (I) was euthyroid without T4 substitution (n = 13), whereas the other (group II) received T4 (n = 9).
Report a problemFND-0268500701
06HumanNon-randomized trialEfficacy outcome
In GH-deficient adults without T4 substitution, GH increased serum T3 from 1.9 to 2.0 nanomoles per L (P less than 0.1).
In plain wordsIn GH-deficient adults without thyroid replacement, GH increased serum T3 compared with placebo, with P less than 0.1.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum T3 without T4 substitution
Study
n = 13
Comparator
Placebo
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
2 IU/m2.day · 4 monthsAs given in this study (human).
Measurements
T3
1.9 nanomoles per L
group I, first value listed
T3
2 nanomoles per L
group I, after GH
Source sentences
Summary
Conversely, GH treatment caused an increase in serum T3 (nanomoles per L) in both groups [group I, 1.9 +/- 0.1 vs. 2.0 +/- 0.1 (P less than 0.1); group II, 1.7 +/- 0.1 vs. 1.9 +/- 0.1 (P less than 0.05)].
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we conducted a double blind, placebo-controlled cross-over study of the effect of 4 months of biosynthetic human GH therapy (Norditropin; 2 IU/m2.day) on thyroid function in GH-deficient adults (8 females and 14 males; mean +/- SE age, 23.8 +/- 1.2 yr).
Summary · context
One group (I) was euthyroid without T4 substitution (n = 13), whereas the other (group II) received T4 (n = 9).
Report a problemFND-0268500703
07HumanNon-randomized trialEfficacy outcome
In GH-deficient adults without T4 substitution, GH reduced rT3 from 0.26 to 0.20 nanomoles per L versus placebo (P less than 0.01).
In plain wordsIn GH-deficient adults without thyroid replacement, GH reduced rT3 compared with placebo.
Peptide
HGH (somatotropin)
Outcome
DecreaseSerum rT3 without T4 substitution
Study
n = 13
Comparator
Placebo
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
2 IU/m2.day · 4 monthsAs given in this study (human).
Measurements
rT3
0.26 nanomoles per L
group I placebo
rT3
0.2 nanomoles per L
group I GH
Source sentences
Summary
Serum rT3 (nanomoles per L) was low in group I and decreased significantly, as in group II, after GH treatment [group I, 0.26 +/- 0.02 (placebo) vs. 0.20 +/- 0.02 (GH; P less than 0.01); group II, 0.38 +/- 0.05 (placebo) vs. 0.29 +/- 0.02 (GH; P less than 0.01)].
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we conducted a double blind, placebo-controlled cross-over study of the effect of 4 months of biosynthetic human GH therapy (Norditropin; 2 IU/m2.day) on thyroid function in GH-deficient adults (8 females and 14 males; mean +/- SE age, 23.8 +/- 1.2 yr).
Summary · context
One group (I) was euthyroid without T4 substitution (n = 13), whereas the other (group II) received T4 (n = 9).
Report a problemFND-0268500707
08HumanNon-randomized trialEfficacy outcome
In GH-deficient adults receiving T4, GH reduced serum T4 from 145 to 115 nanomoles per L (P less than 0.05).
In plain wordsIn GH-deficient adults receiving thyroid replacement, GH reduced serum T4 compared with placebo.
Peptide
HGH (somatotropin)
Outcome
DecreaseSerum T4 with T4 substitution
Study
n = 9
Comparator
Placebo
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
2 IU/m2.day · 4 monthsAs given in this study (human).
Measurements
T4
145 nanomoles per L
group II, first value listed
T4
115 nanomoles per L
group II, after GH
Source sentences
Summary
Serum T4 (nanomoles per L) decreased in both groups after GH treatment [group I, 100 +/- 8 (mean +/- SE) vs. 89 +/- 8 (P less than 0.01); group II, 145 +/- 18 vs. 115 +/- 10 (P less than 0.05)].
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we conducted a double blind, placebo-controlled cross-over study of the effect of 4 months of biosynthetic human GH therapy (Norditropin; 2 IU/m2.day) on thyroid function in GH-deficient adults (8 females and 14 males; mean +/- SE age, 23.8 +/- 1.2 yr).
Summary · context
One group (I) was euthyroid without T4 substitution (n = 13), whereas the other (group II) received T4 (n = 9).
Report a problemFND-0268500702
09HumanNon-randomized trialEfficacy outcome
In GH-deficient adults receiving T4, GH increased serum T3 from 1.7 to 1.9 nanomoles per L (P less than 0.05).
In plain wordsIn GH-deficient adults receiving thyroid replacement, GH increased serum T3 compared with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum T3 with T4 substitution
Study
n = 9
Comparator
Placebo
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
2 IU/m2.day · 4 monthsAs given in this study (human).
Measurements
T3
1.7 nanomoles per L
group II, first value listed
T3
1.9 nanomoles per L
group II, after GH
Source sentences
Summary
Conversely, GH treatment caused an increase in serum T3 (nanomoles per L) in both groups [group I, 1.9 +/- 0.1 vs. 2.0 +/- 0.1 (P less than 0.1); group II, 1.7 +/- 0.1 vs. 1.9 +/- 0.1 (P less than 0.05)].
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we conducted a double blind, placebo-controlled cross-over study of the effect of 4 months of biosynthetic human GH therapy (Norditropin; 2 IU/m2.day) on thyroid function in GH-deficient adults (8 females and 14 males; mean +/- SE age, 23.8 +/- 1.2 yr).
Summary · context
One group (I) was euthyroid without T4 substitution (n = 13), whereas the other (group II) received T4 (n = 9).
Report a problemFND-0268500704
10HumanNon-randomized trialEfficacy outcome
In GH-deficient adults receiving T4, GH reduced rT3 from 0.38 to 0.29 nanomoles per L versus placebo (P less than 0.01).
In plain wordsIn GH-deficient adults receiving thyroid replacement, GH reduced rT3 compared with placebo.
Peptide
HGH (somatotropin)
Outcome
DecreaseSerum rT3 with T4 substitution
Study
n = 9
Comparator
Placebo
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
2 IU/m2.day · 4 monthsAs given in this study (human).
Measurements
rT3
0.38 nanomoles per L
group II placebo
rT3
0.29 nanomoles per L
group II GH
Source sentences
Summary
Serum rT3 (nanomoles per L) was low in group I and decreased significantly, as in group II, after GH treatment [group I, 0.26 +/- 0.02 (placebo) vs. 0.20 +/- 0.02 (GH; P less than 0.01); group II, 0.38 +/- 0.05 (placebo) vs. 0.29 +/- 0.02 (GH; P less than 0.01)].
2 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we conducted a double blind, placebo-controlled cross-over study of the effect of 4 months of biosynthetic human GH therapy (Norditropin; 2 IU/m2.day) on thyroid function in GH-deficient adults (8 females and 14 males; mean +/- SE age, 23.8 +/- 1.2 yr).
Summary · context
One group (I) was euthyroid without T4 substitution (n = 13), whereas the other (group II) received T4 (n = 9).
Report a problemFND-0268500708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.